Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for ...
CytomX Therapeutics, Inc.'s ADC candidate, CX-2051, shows promise in colorectal cancer. Click here to read an analysis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback